Drug Research
Big pharma agrees to drastically cut prices of blockbuster drugs in China
China’s National Healthcare Security Administration (NHSA) has announced it has agreed an average 61% cut in prices of 70 top-selling drugs with large pharma manufacturers in exchange for inclusion on a state-run insurance scheme list.
According to the South China...
Drug Research
FDA approves Aleors Diclofenac sodium topical solution
The US Food and Drug Administration (FDA) has granted tentative approval for Aleor Dermaceuticals’ Diclofenac sodium topical solution USP, 2% w / w to treat the pain of osteoarthritis of the knees.
Aleor is a 60:40 joint venture (JV) between...
Drug Research
Aptar Pharma, Platinum Sponsor at DDL 2019, to Showcase Expanded Portfolio of Respiratory Innovations and Services
Aptar Pharma, a leading drug delivery systems provider, announces its Platinum Sponsorship of this year’s Drug Delivery to the Lung (DDL) Conference 2019, which takes place from December 11-13 in Edinburgh, Scotland.
DDL provides an annual forum for scientists, academics,...
Drug Research
Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors
Hutchison China MediTech Limited announces that the U.S. FDA has granted Orphan Drug designation to surufatinib for the treatment of pancreatic neuroendocrine tumors.
“NET is an area of significant unmet medical need. The current treatment options are very limited,” said...
Drug Research
Bayer and Dewpoint Therapeutics partner to research new treatments for cardiovascular and gynecological diseases
Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, announced an option, research and license agreement worth up to USD 100 million. The partnership will leverage Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s...
Drug Research
DuPont Reveals Enhanced Application and Innovation Center, Increased Production Capacity at CPhI India
DuPont Nutrition & Biosciences has consistently advanced its customers forward by ensuring global access to indispensable ingredients and unmatched expertise. At CPhI India, the company will showcase increased capacity on both fronts, in addition to several product innovations such...
Drug Research
Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases
US-based Dicerna Pharmaceuticals and Novo Nordisk have signed a deal worth up to around $607m to discover and develop drugs for liver-related cardio-metabolic diseases.
In this regard, the companies will make use of GalXC, an RNA interference (RNAi) technology platform...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
